MRI measurement of the uptake and retention of XXXX in @entity463 and uninvolved normal @entity1 brain.

@entity1 @entity41 @entity5 @entity32735 @entity32736 @entity463
PURPOSE: @entity32735 ( @entity32736 ) is an investigational pharmaceutical with radiation enhancing properties. Magnetic Resonance Imaging (MRI) was used to measure brain and @entity5 @entity32736 levels to evaluate (1) the degree to which @entity32736 passes through the intact blood brain barrier, and (2) the retention of @entity32736 in @entity5 in @entity1 with @entity463 ( @entity463 ). METHODS AND MATERIALS: MRI studies were performed on @entity463 @entity1 who participated in a phase I clinical trial in which @entity32736 was given during standard fractionated radiation therapy. @entity32736 was administered daily (Monday to Friday) for five or 10 doses as a loading regimen, followed by three times per week dosing as a maintenance schedule. T1-weighted MRI was performed at intervals throughout the course of the @entity32736 administration and radiation therapy in the 33 participating @entity1 . Eleven @entity1 had pre- and post- @entity32736 scans, allowing for study of @entity32736 's normal blood brain barrier penetration. Twenty-two @entity1 had adequate @entity41 for measurements to evaluate @entity32736 retention in @entity5 during the course of @entity32736 and radiation administration. RESULTS AND CONCLUSIONS: The studies of uninvolved brain tissue support the conclusion that @entity32736 does not cross the intact blood brain barrier in detectable quantities. The @entity5 study showed @entity32736 uptake during loading and maintenance without measurably significant fall off on non-dosage days during the maintenance dosing. Although the number of cases is small, the 10-day loading regimen showed greater drug loading and retention compared with the 5 days loading regimen.
